The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

Hematologists are actively adapting their prescribing strategies in paroxysmal nocturnal hemoglobinuria (PNH), with future pipeline entrants poised to further reshape the treatment landscape ...

Market Barriers Continue to Challenge PNH Treatment Optimization Despite Emerging Options, According to Spherix Global Insights Provided by GlobeNewswire Jul 8, 2025, 11:22:35 AM ...

Hematologists are actively adapting their prescribing strategies in paroxysmal nocturnal hemoglobinuria (PNH), with future pipeline entrants poised to further reshape the treatment landscape.

Apellis and Sobi have amended their partnership agreement for paroxysmal nocturnal hemoglobinuria (PNH) treatment Empaveli, or Aspaveli as it is known in Europe. With the new deal, Stockholm-based ...

The Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in a Complete Response Letter (CRL) for etripamil nasal spray (Cardamyst ™ ), an investigational ...

Join experts as they explore PNH pathophysiology, treatment strategies, clinical trials, and management challenges. Gain essential insights to enhance patient outcomes and optimize PNH treatment.

Omeros Corporation (Nasdaq: OMER) ("Omeros" or the "Company") announced that on July 24, 2025 it entered into a securities ...